Skip to main content

Table 2 Utility Gains Adjusted for Adverse Effects

From: Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia

  VAS SEM SG SEM
Baseline 0.519 0.00725 0.712 0.00578
12 weeks 0.570* 0.00676 0.751 0.00560
24 weeks 0.583* 0.00668 0.762 0.00542
36 weeks 0.594* 0.00658 0.768 0.00551
50 weeks 0.591* 0.00668 0.766 0.00554
Endpoint 0.583* 0.00647 0.763 0.00552
  1. VAS indicates visual analog scale; SEM, standard error of the mean; SG, standard gamble.
  2. *P < 0.001 versus baseline visual-analog-scale measurement (Wilcoxon signed rank test).
  3. P < 0.001 versus baseline standard-gamble measurement (Wilcoxon signed rank test).